Clinical trial Recruiting at 1 site Observational Ages 18 and up

Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis

Official title: Oxidative Stress and Cardiovascular Comorbidity in Patients With Rheumatoid Arthritis

Run by University of La Laguna · NCT07760662 · Data updated 2026-11-12

This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.

More Oxidative Stress trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorUniversity of La Laguna
Academic / other
Drugs / interventionsprednisone
Locations1 site (Santa Cruz de Tenerife, Canary Islands)
StatusRecruiting
StartedJanuary 1, 2024
Main results expectedAugust 1, 2026
Study endsDecember 2026
Registry record updatedAugust 12, 2026
Trial IDNCT07760662 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 to under 70 with rheumatoid arthritis, on stable DMARD therapy (including biologics) and (if on prednisone) 10 mg/day or less for at least one month.

Probably not a fit

Patients not fitting the inclusion criteria or with exclusion conditions (e.g., non-RA autoimmune diseases or severe functional disability) may not derive any direct cardiovascular benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cross-sectional study will enroll adults with rheumatoid arthritis to examine whether serum oxidative stress markers—malondialdehyde, superoxide dismutase, and glutathione peroxidase—are associated with subclinical atherosclerosis and carotid arterial stiffness. The research will also explore how these molecules relate to cardiovascular risk factors such as inflammatory lipid changes, insulin resistance, and beta-cell function. The investigation aims to better understand how oxidative stress may contribute to cardiovascular disease in RA. No interventional treatment is being tested, and the study will describe associations rather than causality. The lead site is Hospital Universitario de Canarias in Tenerife, with the University of La Laguna as sponsor.

Why it matters

Potential benefit: If associations are found, this work could help identify oxidative stress markers that signal higher cardiovascular risk in RA patients.

How similar studies have gone: Previous research has linked oxidative stress and cardiovascular risk in RA, but this specific cross-sectional evaluation of selective biomarkers and subclinical atherosclerosis in RA is a relatively novel synthesis.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men or women who are not pregnant or breastfeeding.
* Age 18 years or older and younger than 70 years.
* Treatment with any disease-modifying antirheumatic drug, including biologic therapies.
* For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion.
* Ability and willingness to provide written informed consent.

Exclusion Criteria:

* Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion.
* Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care.
* History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease.
* Estimated glomerular filtration rate below 60 mL/min/1.73 m² or active renal disease.
* Pregnancy or breastfeeding.
* Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile.
* Body weight greater than 150 kg.
* History of alcoholism, drug abuse, or substance misuse within six months before the screening visit.
* Statin use will not be an exclusion criterion.

Where it's running

  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, Canary Islands, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.